medigraphic.com
ISSN 0016-3813 (Impreso)

2018, Número 4

<< Anterior Siguiente >>

Gac Med Mex 2018; 154 (4)


Importancia del “diagnóstico temprano” en los niños con cáncer para mejorar el pronóstico: concepto con poco sustento científico

Fajardo-Gutiérrez A, Rendón-Macías ME

Idioma: Español
Referencias bibliográficas: 57
Paginas: 520-526
Archivo PDF: 187.56 Kb.


RESUMEN

La mortalidad por cáncer en niños mexicanos no ha disminuido a los niveles informados en países desarrollados. Una explicación frecuentemente declarada es el alto porcentaje (57.3 %) de pacientes diagnosticados en estadios avanzados (III/IV), atribuible a errores en la sospecha o en la metodología empleada, consideración dudosa si se toma en cuenta que el tiempo de diagnóstico y la proporción de estadios avanzados en México son semejantes a los de países desarrollados. En la mayoría de los niños con cáncer, los días transcurridos desde el primer síntoma a momento del diagnóstico oncológico no correlacionan con el estadio clínico y tampoco con la probabilidad de supervivencia. El éxito en la supervivencia depende en gran medida del tratamiento integral (específico y de la atención a las complicaciones). Esta visión obliga a estrategias dirigidas principalmente a invertir más recursos en opciones terapéuticas eficaces y eficientes, capacitación oncológica integral del equipo de salud (médicos, enfermeras, técnicos), tecnologías diagnósticas, fomento a la colaboración interinstitucional e internacional y apoyo socioeconómico a las familias durante el proceso terapéutico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Aguirre A. Enfermedades malignas en la infancia. Su detección temprana. Bol Med Hosp Infant Mex 1965;22:235-245.

  2. Fajardo-Gutiérrez A, Rendon-Macías ME, Mejía-Aranguré JM. Epidemiología del cáncer en niños mexicanos. Resultados globales. Rev Med Inst Mex Seguro Soc. 2011;49:43-70.

  3. Centro Nacional para la Salud de la Infancia y la Adolescencia. [Internet]. Boletín Nacional de Cáncer 2008 a 2012. Disponible en: www.censia. salud.gob mx. Boletín Nacional de Cáncer 2014.

  4. Draper G. Childhood cancer: trends in incidence, survival and mortality. Eur J Cancer. 1995;31:653-654.

  5. Fajardo-Gutiérrez A, González-Miranda G, Pachuca-Vázquez A, Allende- López A, Rendon-Macías ME, Fajardo-Yamamoto LM. Cancer incidence and mortality in children in the Mexican Social Security Institute (1996-2013). Salud Publica Mex. 2016;58:162-170.

  6. Bosetti C, Bertuccio P, Chatenoud L, Negri E, Levi F, La Vecchia C. Childhood cancer mortality in Europe, 1970-2007. Eur J Cancer. 2010;46:384-394.

  7. Chatenoud L, Bertuccio P, Bosetti C, Levi F, Negri E, La Vecchia C. Childhood cancer mortality in America, Asia, and Oceania, 1970 through 2007. Cancer. 2010;116:5063-5074.

  8. Rivera-Luna R, Zapata-Tarres M, Shalkow-Klincovstein J, Velasco-Hidalgo L, Olaya-Vargas A, Cárdenas-Cardós R, et al. The burden of childhood cancer in Mexico: Implications for low- and middle-income countries. Pediatr Blood Cancer. 2017;64 e26366.

  9. Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017;18:719-731.

  10. Dommett RM, Redaniel T, Stevens MC, Martin RM, Hamilton W. Risk of childhood cancer with symptoms in primary care: a population-based case-control study. Br J Gen Pract. 2013;63:22-29.

  11. Feltbower RG, Lewis IJ, Picton S, Richards M, Glaser AW, Kinsey SE, et al. Diagnosing childhood cancer in primary care -a realistic expectation? Br J Cancer. 2004;90(10):1882-1884.

  12. Acha-García T. Diagnóstico precoz y signos de alarma en oncohematología pediátrica. En: Asociación Española de Pediatría de Atención Primaria, ed. Curso de actualización en pediatría 2015. España: Lúa Ediciones; 2015.

  13. Orbach D, Gajdos V, André N. Diagnosis pitfalls and emergencies in children with cancer. Rev Prat. 2014;64:1276-1286.

  14. Wilne S, Koller K, Collier J, Kennedy C, Grundy R, Walker D. The diagnosis of brain tumours in children: a guideline to assist healthcare professionals in the assessment of children who may have a brain tumour. Arch Dis Child. 2010;95:534-539.

  15. Hamilton W, Hajioff S, Graham J, Schmidt-Hansen M. Suspected cancer (part 1-children and young adults): visual overview of updated NICE guidance. BMJ. 2015;350:h3036-h3036.

  16. Lethaby CD, Picton S, Kinsey SE, Phillips R, Van-Laar M, Feltbower RG. A systematic review of time to diagnosis in children and young adults with cancer. Arch Dis Child. 2013;98:349-355.

  17. Dixon-Woods M, Findlay M, Young B, Cox H, Heney D. Parents’ accounts of obtaining a diagnosis of childhood cancer. Lancet. 2001;357:670-674.

  18. Ahrensberg JM, Olesen F, Hansen RP, Schrøder H, Vedsted P. Childhood cancer and factors related to prolonged diagnostic intervals: a Danish population-based study. Br J Cancer. 2013;108:1280-1287.

  19. Ahrensberg JM, Fenger-Grøn M, Vedsted P. Primary care use before cancer diagnosis in adolescents and young adults - a nationwide register study. PLoS One. 2016;11:e0155933.

  20. Bragonier R, Cordey E. Suspected childhood cancer fast track: increasing referrals, diminishing returns. Arch Dis Child. 2015;100:900-901.

  21. Chen J, Mullen CA. Patterns of diagnosis and misdiagnosis in pediatric cancer and relationship to survival. J Pediatr Hematol Oncol. 2017;39:e110-e115.

  22. Dang-Tan T, Franco EL. Diagnosis delays in childhood cancer: a review. Cancer. 2007;110:703-713.

  23. Pollock BF, Krischer JP, Vietti T. Interval between symptom onset and dianosis of pediaric solid tumors. J Pediatr. 1991;119:725-732.

  24. Fajardo-Gutiérrez A, Sandoval-Mex AM, Mejía-Aranguré JM, Rendón- Macías ME, Martínez-García MC. Clinical and social factors that affect the time to diagnosis of Mexican children with cancer. Med Pediatr Oncol. 2002;39:25-31.

  25. Vásquez L, Oscanoa M, Tello M, Tapia E, Maza I, Gerónimo J. Factors associated with the latency to diagnosis of childhood cancer in Peru. Pediatr Blood Cancer. 2016;11:1959-1965.

  26. Castro-Jimenez MA, Rueda-Arenas E, Cabrera-Rodríguez D. Aproximación a la semiología clínica prediagnóstica, advertida por la madre, de la leucemia linfoide aguda pediátrica. Arch Argent Pediatr. 2015; 113:331-336.

  27. Haimi M, Pérez-Nahum M, Stein N, Ben Arush MW. The role of the doctor and the medical system in the diagnostic delay in pediatric malignancies. Cancer Epidemiol. 2011;35:83-89.

  28. Brown BJ, James BO, Ajayi SO, Ogun O a, Oladokun RE. Factors influencing time to diagnosis of childhood cancer in Ibadan, Nigeria. Afr Health Sci. 2009;9:247-253.

  29. Reaman GH. What, why, and when we image: considerations for diagnostic imaging and clinical research in the Children’s Oncology Group. Pediatr Radiol. 2009;39:42-45.

  30. Klein-Geltink JE, Pogany LM, Barr RD, Greenberg ML, Mery LS. Waiting times for cancer care in Canadian children: Impact of distance, clinical, and demographic factors. Pediatr Blood Cancer. 2005;44:318-327.

  31. Venkatasai JP, Srinivasamaharaj S, Sneha LM, Scott JX, Baby A, Rajan M. Pediatric hematological malignancy: Identification of issues involved in the road to diagnosis. South Asian J Cancer. 2017;6:28-30.

  32. Rendón-Macías ME, Valencia-Ramón EA, Fajardo-Gutiérrez A. Clinical and epidemiological characteristics of Burkitt lymphomas in pediatric patients from two defined socioeconomic regions in Mexico. J Trop Pediatr. 2017;63:253-259.

  33. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385:977-1010.

  34. Valdez-Ramires L. Tiempo transcurrido entre el inicio de los síntomas y signos, diagnóstico, estadio e inicio del tratamiento en niños con cáncer atendidos en el Instituto Mexicano del Seguro Social. Tesis para obtener el grado de Maestría en Ciencias en Epidemiología, Universidad Nacional Autónoma de México, 2006.

  35. Ferrari A, Lo Vullo S, Giardiello D, Veneroni L, Magni C, Clerici CA, et al. The sooner the better? How symptom interval correlates with outcome in children and adolescents with solid tumors: regression tree analysis of the findings of a prospective study. Pediatr Blood Cancer. 2015; 63:479-485.

  36. Halperin EC, Watson DM, George SL, Watson DM. Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma. Cancer. 2001;91:1444-1450.

  37. Saha V, Love S, Eden T, Micallef-Eynaud P, MacKinlay G. Determinants of symptom interval in childhood cancer. Arch Dis Child. 1993;58:771-774.

  38. Brasme JF, Grill J, Doz F, Lacour B, Gaillard S, Delalande O, et al. Long time to diagnosis of medulloblastoma in children is not associated with decreased survival or with worse neurological outcome. PLoS One. 2012;7:e33415.

  39. Rendon-Macías ME, Valencia-Ramón EA, Fajardo-Gutiérrez A, Castro- Ríos A. Incidence of childhood hodgkin lymphoma in Mexico by histologic subtypes and socioeconomic regions. J Pediatr Hematol Oncol. 2015;38:e93-e101.

  40. Bacci G, Ferrari S, Longhi A, Forni C, Zavatta M, Smith K, et al. High-grade osteosarcoma of the extremity: differences between localized and metastatic tumors at presentation. J Pediatr Hematol Oncol. 2002;24:27-30.

  41. Brasme JF, Gaspar N, Oberlin O, Valteau-Couanet D, Chalumeau M, Grill J. Evidence of increasing mortality with longer time to diagnosis of cancer: is there a paediatric exception? Eur J Cancer. 2014;50:864-866.

  42. Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Hendry A, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer. 2015;112:S92-S107.

  43. Kukal K, Dobrovoljac M, Boltshauser E, Ammann RA, Grotzer MA. Does diagnostic delay result in decreased survival in paediatric brain tumours? Eur J Pediatr. 2009;168:303-310.

  44. Gupta S, Gibson P, Pole JD, Sutradhar R, Sung L GA. Predictors of diagnostic interval and associations with outcome in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62:957-963.

  45. Lins MM, Amorim M, Vitela P, Viana M, Ribeiro RC, Pedrosa A, et al. Delayed diagnosis of leukemia and association with morbid-mortality in children in Pernambuco, Brazil. J Pediatr Hematol Oncol. 2012; 34:e271-e276.

  46. Baker JM, To T, Beyene J, Zagorski B, Geenberg ML, Sung L. Influence of length oftime to diagnosis and treatment on the survival of children with acute lymphoblastic leukemia: a population-base study. Leuk Res. 2014;38:204-209.

  47. Leander C, Fu LC, Peña A, Hoard SC, Rodríguez-Galindo C, Wilimas JA, et al. Impact of an education program on late diagnosis of retinoblastoma in Honduras. Pediatr Blood Cancer. 2007;49:817-819.

  48. Kundra M, Stankovic C, Gupta N, Thomas R, Hamre M, Mahajan P. Epidemiologic findings of cancer detected in a Peditric Emergency Department. Clin Peditr. 2008;48:404-409.

  49. Bragonier R, Cordey E. Suspected childhood cancer fast track: increasing referrals, dismishing returns. Arch Dis Child. 2015;100:900-901.

  50. Mu PF, Lee MY, Shen CC, Tung PC, Huang LY, CYW. The experiences of family members in the year following he diagnosis of a child or adolescent with cancer: a qualitative systematic review. JBI Database System Rev Implement Rep. 2015;13:293-329.

  51. Fawkner-Corbett DW, Howell L, Pizar BL, Dominici C, McDowell HP, Losty P. Wilms’ tumor-lessons and outcomes-a 25-year single center UK experience. Peditric Hematol Oncol. 2014;31:400-408.

  52. Schwartz CL, Chen L, McCarten K, Wolden S, Constine LS, Keller FG, et al. Childhood Hodgkin International Prognostic Score (CHIPS) predicts event-free survival in Hodgkin lymphoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2017;64:e26278.

  53. Schindler M, Belle FN, Grotzer MA, Von-Der-Weid NX, Kuehni CE. Childhood cancer survival in Switzerland (1976–2013): time-trends and predictors. Int J Cancer. 2017;140 62-74.

  54. Roskin J, Diviney J, Nanduri V. Presentation of childhood cancers to a paediatric shared care unit. Arch Dis Child. 2015;100:1131-1135.

  55. Spencer S, Nypaver M, Hebert K, Benner C, Stanley R, Cohen D, et al. Successful emergency department interventions that reduce time to antibiotics in febrile pediatric cancer patients. BMJ Qual Improv Rep. 2017;6:u212406.w4933.

  56. Ribeiro RC, Antillon F, Pedrosa F, Pui CH. Global pediatric oncology: lessons from partnerships between high-income countries and low-to mid-income countries. J Clin Oncol. 2016;34:53-61.

  57. Shulman LN, Wagner CM, Barr R, Lopes G, Longo G, Robertson J, et al. Proposing essential medicines to treat cancer: methodologies, processes, and outcomes. J Clin Oncol. 2016;34:69-75.




2020     |     www.medigraphic.com